论文部分内容阅读
目的研究稳定期COPD患者吸入布地奈德后的FEV1的改善情况。方法选择稳定期COPD患者145例,根据支气管激发试验结果将病人分为伴气道高反应(BHR)和不伴BHR两组,再将伴BHR病人和不伴BHR病人分别分为治疗组和对照组。治疗组每日给予布地奈德气雾剂800mg吸入,对照组仅给予万托林在必要时吸入,治疗6个月后检查FEV1并进行比较分析。结果伴BHR患者经过一个疗程的治疗后,治疗组FEV1与对照组比较有改善,经统计学检验差异有显著性(P<0.05),不伴BHR患者治疗后FEV1变化不明显,与对照组比较差异无显著性(P>0.5)。结论临床上应该根据支气管激发试验对COPD患者进行分类,将伴BHR者给予吸入糖皮质激素治疗,以改善肺功能、延缓疾病发展。
Objective To investigate the improvement of FEV1 after budesonide inhalation in stable COPD patients. Methods A total of 145 patients with stable COPD were enrolled. According to the results of bronchial provocation test, patients were divided into two groups: high airway response (BHR) and no BHR. Patients with and without BHR were divided into treatment group and control group group. In the treatment group, inhalation of budesonide aerosol 800 mg was given daily, while in the control group only vetotriptine was inhaled when necessary. After 6 months of treatment, FEV1 was inspected and comparatively analyzed. Results After treatment with BHR for one course of treatment, FEV1 in the treatment group improved compared with the control group, and the difference was statistically significant (P <0.05). The changes of FEV1 in patients without BHR after treatment were not significantly different from those in the control group No significant difference (P> 0.5). Conclusions Clinically, patients with COPD should be classified according to the bronchial provocation test. Inhaled glucocorticoid therapy should be given to patients with BHR to improve pulmonary function and delay the development of the disease.